Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema

201029 citationsReviewbronze Open Access

Authors

Laura A. Teasley · Bay Area Retina Associates

Abstract

Intravitreal bevacizumab injection is effective in improving VA in patients with primary DMO for 6 weeks, but the benefits are no longer present 12 weeks following the injection.

Topics & Keywords

Retinal Diseases and Treatments Retinal Imaging and Analysis Ocular Diseases and Behçet’s Syndrome

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Acta Ophthalmologica

Volume 89, Issue 8, pp. 709-717

DOI: 10.1111/j.1755-3768.2010.01918.x

Field-Weighted Citation Impact: 2.22